Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
Exscientia plc announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United…